Cladribine

Drug Profile

Cladribine

Alternative Names: 2-CdA; 2-Chlorodeoxyadenosine; Chlorodeoxyadenosine; Intocel; Leustat; Leustatin; Leustatine; Movectro; Mylinax; N-l-Leucyl-doxorubicin; RWJ 26251

Latest Information Update: 23 Nov 2016

Price : $50

At a glance

  • Originator Scripps Clinic
  • Developer EMD Serono; Janssen-Cilag; Merck Serono; Orphan Australia
  • Class Antineoplastics; Deoxyadenosines; Purine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Immunosuppressants; Purinergic P1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple sclerosis; Leukaemia; Lymphoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Multiple sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Hairy cell leukaemia; Leukaemia; Lymphoma; Multiple sclerosis
  • No development reported Psoriasis; Transplant rejection

Most Recent Events

  • 16 Sep 2016 New efficacy data from the phase III ORACLE-MS trial in Multiple sclerosis were presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2016)
  • 16 Sep 2016 New pooled efficacy data from the phase III CLARITY and CLARITY- EXTENSION trial in Multiple sclerosis were presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2016)
  • 14 Sep 2016 Pooled adverse events data from the phase III CLARITY, CLARITY EXTENSION, ORACLE-MS and PREMIERE trials in Multiple sclerosis presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top